Treatment-related serious adverse events in ocular safety, the primary endpoints in a 12-month safety clinical trial of reproxalap for the treatment of dry eye disease, were not observed, according to an Aldeyra Therapeutics press release.
The trial included 447 patients with dry eye disease, with 299 receiving reproxalap and 148 receiving vehicle. The ocular safety events were consistent across both groups, and no safety concerns have been identified in more than 2,300 patients who have received reproxalap.
In a post hoc analysis, reproxalap was superior to vehicle in improvement in distance